Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance

10 Jul 2009

Abstract excerpt

BACKGROUND: Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu). Up to 70% of Her2-positive breast cancers demonstrate a response to Herceptin-based therapies, but resistance almost inevitably arises within a year of the initial response. To help understand the mechanism of Herceptin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen and related hormone effects
Share to HER2/EGFR in Cancer Research
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19593441
DOI: 10.1371/journal.pone.0006220

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin ResistancePMID 19593441Read ↗

Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathwaysSemantic proximity Read ↗

Modelling the role of dual specificity phosphatases in Herceptin resistant breast cancer cell linesSemantic proximity Read ↗

PP1, PKA and DARPP‐32 in breast cancer: A retrospective assessment of protein and mRNA expressionSemantic proximity Read ↗

Ceramide-induced Endoplasmic Reticulum Stress as a Targetable Vulnerability in Endocrine Therapy-Resistant Breast CancerSemantic proximity Read ↗

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].Semantic proximity Read ↗

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.Semantic proximity Read ↗

PP2A inhibition overcomes acquired resistance to HER2 targeted therapySemantic proximity Read ↗

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast CancerSemantic proximity Read ↗

Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cellsSemantic proximity Read ↗

Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stabilitySemantic proximity Read ↗

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.Semantic proximity Read ↗

Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.